Pharmacoinvasive strategy in the treatment of acute myocardial infarction: current state-of-the-art
https://doi.org/10.15829/1560-4071-2021-4452
Abstract
The existing clinical guidelines identify two main approaches to the treatment of patients with ST-segment elevation myocardial infarction: a primary percutaneous coronary intervention and a pharmacoinvasive strategy. Due to the time delays due to various reasons, it is not always easy to perform primary percutaneous coronary intervention timely (<120 minutes). Modern thrombolytic drugs make it easy and safe to apply a pharmacoinvasive strategy to a wide group of patients, improving their prognosis.
About the Authors
A. S. Tereshchenko
National Medical Center of Cardiology
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
not
T. M. Uskach
National Medical Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
not
N. V. Kondratova
Medicine, JSC; Pirogov Russian National Research Medical University
Russian Federation
Competing Interests:
Russian Federation
Moscow
Competing Interests:
not
References
1. Арутюнян Г. К., Меркулов Е. В. Инвазивное лечение ишемической болезни сердца. В кн.: Сергиенко И. В., Аншелес А. А., Кухарчук В. В. Дислипидемии, атеросклероз и ишемическая болезнь сердца: современные аспекты патогенеза, диагностики и лечения. М., 2018, 158-94, ISBN: 978-5-90363366-1.
2. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11 ):4103. doi:10.15829/29/1560-4071-2020-4103.
3. Терещенко А. С., Меркулов Е. В., Самко А. Н. и др. Возможность применения новых антиагрегантов у пациентов после проведения планового чрескожного коронарного вмешательства. Эндоваскулярная хирургия. 2020;7(1):14-23. doi:10.24183/2409-4080-2020-7-1-14-23.
4. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-e646. doi:10.1161/CIR.0000000000000678.
5. Wong GC, Welsford M, Ainsworth C, et al. CCS/CAIC STEMI Guidelines. Canadian Journal of Cardiology. 2019;35(2):107-32. doi:10.1016/j.cjca.2018.11.031.
6. Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.
7. Алекян Б. Г., Ганюков В. И., Маношкина Е. М. и др. Реваскуляризация при инфаркте миокарда с подъемом сегмента ST в Российской Федерации. Анализ результатов 2018 года. Эндоваскулярная хирургия. 2019;6(2):89-97 doi: 10.24183/2409-4080-2019-6-2-89-97.
8. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.
9. Edfors R, James S, Szummer K, et al. SWEDEHEART-1-year data show no benefit of newer generation drug-eluting stents over bare-metal stents in patients with severe kidney dysfunction following percutaneous coronary intervention. Coronary Artery Disease. 2020;31(1):49-58. doi:10.1097/MCA.0000000000000814.
10. Kristensen S, Laut K, Fajadet J, et al. Reperfusion therapy for ST elevation acutemyo-cardial infarction 2010/2011: current status in 37 ESC countries. Eur. Heart J. 2014;35(29):1957-70. doi:10.1093/eurheartj/eht529.
11. Doll JA, Roe MT. Time to treatment as a quality metric for acute STEMI care. Lancet. 2015;385(9973):1056-7. doi:10.1016/S0140-6736(14)62051-1.
12. Terkelsen CJ, Sorensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763-71. doi:10.1001/jama.2010.1139.
13. Siddiqi TJ, Usman MS, Khan MS, et al. Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction. Am J Cardiol. 2018;122(4):542-7 doi:10.1016/j.amjcard.2018.04.057.
14. Bainey KR, Armstrong PW, Zheng Y, et al. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry. CircCardiovascInterv. 2019;12(10):e008059. doi:10.1161/CIRCINTERVENTIONS.119.008059.
15. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J. 2009;30:1598-606. doi:10.1007/s11936-014-0302-9.
16. Armstrong PW. WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530-8. doi:10.1093/eurheartj/ehl088.
17. Danchin N, Coste P, Ferrieres J, et al. FAST-MI Investigators Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation. 2008;118(3):268-76. doi:10.1161/CIRCULATIONAHA.107.762765.
18. Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092.
19. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673-82. doi:10.1056/NEJM199309023291001.
20. Handbook of medicinal products. Information about medicines with the registration certificate number LP-00194. (In Russ.) Справочник лекарственных препаратов. Информация о лекарственных препаратах с номером регистрационного удостоверения ЛП-00194. https://medum.ru/lp-001941.
21. Van de Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double blind randomised trial. Lancet. 1999;354(9180):716-22. doi:10.1016/s0140-6736(99)07403-6.
22. Sinnaeve P, Alexander J, Belmans A, et al. ASSENT-2 Investigators. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecte-plase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. Am Heart J. 2003;146(1):27-32. doi:10.1016/S0002-8703(03)00117-0.
23. Wong Ch-K, White HD. Acute myocardial infarction: Fibrinolytic therapy. Current Treatment Options in Cardiovascular Medicine. 2004;6:15-28.
24. Алексеева Я. В., Вышлов Е. В., Марков В. А. Рекомбинантная неиммуногеннаястафилокиназа в лечении острого инфаркта миокарда. Сибирский журнал клинической и экспериментальной медицины. 2016;31(2):51-4. doi:10.29001/2073-8552-2016-31-2-51-54.
Review
For citations:
Tereshchenko A.S., Uskach T.M., Kondratova N.V. Pharmacoinvasive strategy in the treatment of acute myocardial infarction: current state-of-the-art. Russian Journal of Cardiology. 2021;26(2S):4452. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4452
Views:
1859
Email this article 